ArticleScientific reports2025
TIR-domain-containing protein C as modulator of innate immune checkpoints.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TIR-domain-containing protein C (TcpC), a virulence factor of the uropathogenic Escherichia coli strain CFT073, binds to crucial components of the toll-like receptor-signaling cascade and the NLRP3 inflammasome thus manipulating these innate immune checkpoints and their immune responses. Here we show that TcpC intensified TLR4-dependent pro-inflammatory cytokine secretion by human epithelial cells upon infection with CFT073. Furthermore, TcpC amplified immune responses of monocytic THP-1 cells and peripheral blood mononuclear cells and monocytes during infection. Interestingly, differentiation of monocytes to M0 macrophages reduced the influence of TcpC on innate immune responses. Similarly, polarization of monocytic THP-1 to M1 macrophages impaired partially the ability of TcpC to modulate cytokine secretion. Induced expression of TcpC revealed that increasing levels of TcpC induction augmented the stimulation of THP-1 cells during infection. In contrast, transfer of TcpC-containing culture supernatants from CFT073 to endotoxin plus ATP-stimulated monocytic THP-1 cells revealed the inhibitory function of TcpC. In summary, we show here that TcpC strengthens cytokine release during infection but dampens it during endotoxin-stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.